Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro

L. Herrera, R. A. Farah, V. A. Pellegrini, D. B. Aquino, E. S. Sandler, G. R. Buchanan, E. S. Vitetta

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Monoclonal antibodies (Mabs) conjugated to toxins or their subunits (immunotoxins or ITs) are undergoing clinical testing in adults with a variety of malignancies. The potential impact of this form of therapy in pediatric precursor B-lineage acute lymphoblastic leukemia (pre-B ALL) has yet to be determined. Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in patients with pre-B ALL. Because of the encouraging performance of these ITs in phase I trials, we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient-derived pre-B ALL cells maintained in vitro on a stromal feeder layer. After 48 h in culture, cytotoxicity to tumor cells was determined by flow cytometry using propidium iodide (PI) and fluorescein isothiocyanate (FITC)-conjugated anti-CD10, 19, and 22. Both RFB4-dgRTA and HD37-dgRTA induced a statistically significant reduction in the number of viable leukemic cells, and Combotox was even more effective. Our results demonstrate that these ITs are specifically cytotoxic to primary pre-B ALL cells and that they should be further evaluated for the therapy of B-lineage ALL.

Original languageEnglish (US)
Pages (from-to)853-858
Number of pages6
JournalLeukemia
Volume14
Issue number5
StatePublished - 2000

Fingerprint

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Immunotoxins
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monoclonal Antibodies
Feeder Cells
Ricin
Propidium
Surface Antigens
Fluorescein
Non-Hodgkin's Lymphoma
Neoplasms
Flow Cytometry
Pediatrics
In Vitro Techniques
Therapeutics

Keywords

  • Childhood leukemia
  • Immunotherapy
  • Immunotoxins
  • Monoclonal antibodies
  • Pre-B ALL

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. / Herrera, L.; Farah, R. A.; Pellegrini, V. A.; Aquino, D. B.; Sandler, E. S.; Buchanan, G. R.; Vitetta, E. S.

In: Leukemia, Vol. 14, No. 5, 2000, p. 853-858.

Research output: Contribution to journalArticle

Herrera, L, Farah, RA, Pellegrini, VA, Aquino, DB, Sandler, ES, Buchanan, GR & Vitetta, ES 2000, 'Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro', Leukemia, vol. 14, no. 5, pp. 853-858.
Herrera, L. ; Farah, R. A. ; Pellegrini, V. A. ; Aquino, D. B. ; Sandler, E. S. ; Buchanan, G. R. ; Vitetta, E. S. / Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. In: Leukemia. 2000 ; Vol. 14, No. 5. pp. 853-858.
@article{b8ec0b81285f48138cba24539fbb6c0e,
title = "Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro",
abstract = "Monoclonal antibodies (Mabs) conjugated to toxins or their subunits (immunotoxins or ITs) are undergoing clinical testing in adults with a variety of malignancies. The potential impact of this form of therapy in pediatric precursor B-lineage acute lymphoblastic leukemia (pre-B ALL) has yet to be determined. Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in patients with pre-B ALL. Because of the encouraging performance of these ITs in phase I trials, we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient-derived pre-B ALL cells maintained in vitro on a stromal feeder layer. After 48 h in culture, cytotoxicity to tumor cells was determined by flow cytometry using propidium iodide (PI) and fluorescein isothiocyanate (FITC)-conjugated anti-CD10, 19, and 22. Both RFB4-dgRTA and HD37-dgRTA induced a statistically significant reduction in the number of viable leukemic cells, and Combotox was even more effective. Our results demonstrate that these ITs are specifically cytotoxic to primary pre-B ALL cells and that they should be further evaluated for the therapy of B-lineage ALL.",
keywords = "Childhood leukemia, Immunotherapy, Immunotoxins, Monoclonal antibodies, Pre-B ALL",
author = "L. Herrera and Farah, {R. A.} and Pellegrini, {V. A.} and Aquino, {D. B.} and Sandler, {E. S.} and Buchanan, {G. R.} and Vitetta, {E. S.}",
year = "2000",
language = "English (US)",
volume = "14",
pages = "853--858",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro

AU - Herrera, L.

AU - Farah, R. A.

AU - Pellegrini, V. A.

AU - Aquino, D. B.

AU - Sandler, E. S.

AU - Buchanan, G. R.

AU - Vitetta, E. S.

PY - 2000

Y1 - 2000

N2 - Monoclonal antibodies (Mabs) conjugated to toxins or their subunits (immunotoxins or ITs) are undergoing clinical testing in adults with a variety of malignancies. The potential impact of this form of therapy in pediatric precursor B-lineage acute lymphoblastic leukemia (pre-B ALL) has yet to be determined. Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in patients with pre-B ALL. Because of the encouraging performance of these ITs in phase I trials, we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient-derived pre-B ALL cells maintained in vitro on a stromal feeder layer. After 48 h in culture, cytotoxicity to tumor cells was determined by flow cytometry using propidium iodide (PI) and fluorescein isothiocyanate (FITC)-conjugated anti-CD10, 19, and 22. Both RFB4-dgRTA and HD37-dgRTA induced a statistically significant reduction in the number of viable leukemic cells, and Combotox was even more effective. Our results demonstrate that these ITs are specifically cytotoxic to primary pre-B ALL cells and that they should be further evaluated for the therapy of B-lineage ALL.

AB - Monoclonal antibodies (Mabs) conjugated to toxins or their subunits (immunotoxins or ITs) are undergoing clinical testing in adults with a variety of malignancies. The potential impact of this form of therapy in pediatric precursor B-lineage acute lymphoblastic leukemia (pre-B ALL) has yet to be determined. Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in patients with pre-B ALL. Because of the encouraging performance of these ITs in phase I trials, we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient-derived pre-B ALL cells maintained in vitro on a stromal feeder layer. After 48 h in culture, cytotoxicity to tumor cells was determined by flow cytometry using propidium iodide (PI) and fluorescein isothiocyanate (FITC)-conjugated anti-CD10, 19, and 22. Both RFB4-dgRTA and HD37-dgRTA induced a statistically significant reduction in the number of viable leukemic cells, and Combotox was even more effective. Our results demonstrate that these ITs are specifically cytotoxic to primary pre-B ALL cells and that they should be further evaluated for the therapy of B-lineage ALL.

KW - Childhood leukemia

KW - Immunotherapy

KW - Immunotoxins

KW - Monoclonal antibodies

KW - Pre-B ALL

UR - http://www.scopus.com/inward/record.url?scp=0034090987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034090987&partnerID=8YFLogxK

M3 - Article

C2 - 10803517

AN - SCOPUS:0034090987

VL - 14

SP - 853

EP - 858

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -